New drug combo aims to boost breast cancer remission before surgery
NCT ID NCT07307287
First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery for women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. About 30 women will participate, and the study will also monitor side effects and long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.